Physician profile
William Tony Mckenzie
NPI 1326060682
$360,826.89
in general payments reported to CMS, 2019-2025
31 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $39K · 2021: $28K · 2022: $28K · 2023: $43K · 2024: $62K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $149K · Food and Beverage: $8,005 · Travel and Lodging: $6,452 · Honoraria: $2,500 · Consulting Fee: $200 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $149,479.22 |
| Food and Beverage | $8,005.40 |
| Travel and Lodging | $6,451.89 |
| Honoraria | $2,500.00 |
| Consulting Fee | $200.00 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $173,978.33 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Mylan Specialty L.P. | $95,226.12 | 2019-2024 | Yupelri, Yupelri |
| Sunovion Pharmaceuticals INC. | $20,608.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20,516.58 | 2020-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,742.98 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Shire North American Group INC | $12,583.68 | 2019 | |
| Grifols USA, LLC | $8,731.03 | 2020-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $4,957.26 | 2025 | Yupelri |
| Verona Pharma, INC. | $2,780.70 | 2025 | Ohtuvayre |
| Grifols Shared Services North America, INC. | $660.00 | 2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $599.42 | 2019-2025 | Trelegy Ellipta |
| Genzyme Corporation | $353.96 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $307.11 | 2019-2025 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $244.35 | 2023-2025 | Lumryz |
| Electromed, INC. | $225.39 | 2019-2025 | Smartvest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $191.93 | 2022-2024 | Wakix |
| Vifor Pharma, INC. | $176.64 | 2024-2025 | Zemaira, Veltassa |
| Astellas Pharma US INC | $139.13 | 2025 | Veozah |
| Amgen INC. | $130.68 | 2022-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $120.39 | 2019-2021 | |
| 3b Medical, INC. | $99.89 | 2023-2025 | Luna |
| Insmed, INC. | $94.18 | 2021-2025 | Arikayce |
| Sumitomo Pharma America, INC. | $83.86 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $56.54 | 2021-2022 | |
| Philips North America LLC | $56.14 | 2019-2020 | |
| Inspire Medical Systems, INC. | $54.78 | 2025 | Inspire |
| Fisher & Paykel Healthcare INC | $32.26 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $26.88 | 2022 | |
| United Therapeutics Corporation | $20.42 | 2022 | |
| Inogen, INC. | $14.80 | 2022 | |
| Eisai INC. | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.